Drug intelligence / Profile preview

AK130H1

Development stage: Preclinical
Lead developer: Akeso
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AK130H1 is an investigational antibody-drug conjugate (ADC) developed by Akeso Biopharma that targets the Human Epidermal Growth Factor Receptor 3 (HER3). It is designed to deliver a cytotoxic payload specifically to tumor cells expressing HER3, a member of the EGFR family that is frequently overexpressed in various solid tumors and implicated in treatment resistance. Upon binding to the extracellular domain of HER3, the ADC is internalized, leading to the intracellular release of the payload and subsequent cell death. AK130H1 is currently being evaluated for the treatment of advanced solid tumors.

Other names: Akeso HER3-ADC

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on AK130H1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK130H1.

Explore the full profile